Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of >100,000 individuals.

Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of >100,000 individuals. J Crohns Colitis. 2018 Oct 13;: Authors: Aarestrup J, Jess T, Kobylecki CJ, Nordestgaard BG, Allin KH Abstract Background and Aims: Patients with inflammatory bowel disease have increased risks of cardiovascular diseases but the role of traditional and non-traditional cardiovascular risk factors remains unclear. We investigated if the cardiovascular risk profile differs between patients with inflammatory bowel disease and individuals in the general population. Methods: We included a population of 108,789 participants from The Copenhagen…

Read More

Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease. A multivariate analysis in 4 expert centres in Europe.

Risk factors for small bowel obstruction after laparoscopic ileal pouch-anal anastomosis for inflammatory bowel disease. A multivariate analysis in 4 expert centres in Europe. J Crohns Colitis. 2018 Oct 11;: Authors: Mege D, Colombo F, Stellingwerf ME, Germain A, Maggiori L, Foschi D, Buskens CJ, de Buck van Overstraeten A, Sampietro G, D’Hoore A, Bemelman W, Panis Y Abstract Background and Aims: Although laparoscopic a1pproach is associated with the reduction of adhesions, no data are available about risk factors for small bowel obstruction (SBO) after laparoscopic ileal pouch-anal anastomosis (IPAA).…

Read More

GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD.

GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD. J Crohns Colitis. 2018 Oct 11;: Authors: Dierckx T, Verstockt B, Vermeire S, van Weyenbergh J Abstract Background and aims: Glycoprotein acetylation (GlycA) is a novel nuclear magnetic resonance (NMR) biomarker measured in serum or plasma, which summarizes signal originating from glycan groups of certain acute phase glycoproteins. This biomarker has been shown to be robustly associated to cardiovascular and short-term all-cause mortality, and to disease severity in several inflammatory conditions.…

Read More

Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study.

Access to Specialists and Emergency Department Visits in Inflammatory Bowel Disease: A Population-Based Study. J Crohns Colitis. 2018 Oct 12;: Authors: Nguyen GC, Bouchard S, Diong C, Promoting Access and Care through Centres of Excellence (PACE) Network Abstract Background and Aims: The number of inflammatory bowel disease (IBD) related visits to the emergency department (ED) is increasing in North America. Our study evaluates the relationship between access to specialists and utilization of ED services. Methods: We conducted a population-based study of all IBD patients in the Ontario in 2014-2015 to…

Read More

Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review.

Clinical usefulness of proteomics in inflammatory bowel disease: A comprehensive review. J Crohns Colitis. 2018 Oct 10;: Authors: Gisbert JP, Chaparro M Abstract The protein domain is likely the most ubiquitously affected in disease, response and recovery, and therefore proteomics holds special promise for biomarker discovery in general, and particularly in inflammatory bowel disease (IBD), i.e., ulcerative colitis and Crohn’s disease. Tremendous progress has been made over the past decade in the development and refinement of proteomic technologies. These advances provide opportunities for a long-anticipated personalized medicine approach to the…

Read More

A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn’s disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).

A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn’s disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). J Crohns Colitis. 2018 Oct 06;: Authors: Macaluso FS, Fries W, Privitera AC, Cappello M, Siringo S, Inserra G, Magnano A, Di Mitri R, Mocciaro F, Belluardo N, Scarpulla G, Magrì G, Trovatello A, Carroccio A, Genova S, Bertolami C, Vassallo R, Romano C, Citrano M, Accomando S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Porcari S, Ferracane C, Cottone…

Read More

Colitis alters oxysterol metabolism and is affected by 4β-hydroxycholesterol administration.

Colitis alters oxysterol metabolism and is affected by 4β-hydroxycholesterol administration. J Crohns Colitis. 2018 Oct 06;: Authors: Guillemot-Legris O, Mutemberezi V, Buisseret B, Paquot A, Palmieri V, Bottemanne P, Lemaire J, Rahier JF, Alhouayek M, Muccioli GG Abstract Background and aims: Inflammatory bowel diseases (IBD) represent a challenging health issue with a complex etiology implicating genetic and environmental parameters. Although the understanding of their pathophysiology has improved, much remains to be explored. In this context, bioactive lipids, more specifically oxysterols, i.e. oxygenated derivatives of cholesterol, represent an interesting avenue to…

Read More

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.

Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. J Crohns Colitis. 2018 Oct 05;: Authors: Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D’Incà R, Salupere R, Zammit SC, Ellul P, Duricova D, Bortlik M,…

Read More

Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis.

Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis. J Crohns Colitis. 2018 Oct 04;: Authors: Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K Abstract Background and Aims: This GEMINI 1 post hoc analysis evaluated vedolizumab efficacy for inducing deep remission in patients with ulcerative colitis and correlation between vedolizumab trough concentrations and deep remission rates. Methods: Week 6 vedolizumab responders were re-randomised to placebo or vedolizumab every 8 or 4 weeks.…

Read More

Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies.

Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies. J Crohns Colitis. 2018 Oct 04;: Authors: Armuzzi A, Avedano L, Greveson K, Kang T Abstract The increasing prevalence of inflammatory bowel disease and the high costs associated with biological therapies suggest that biologicals with lower costs, but no compromise on efficacy and safety, should be considered when developing a treatment plan for inflammatory bowel disease. Biosimilars offer a more cost-effective alternative, and although the European Medicines Agency has approved the use of…

Read More
<< Go Back